SG11201705928XA - 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) - Google Patents

4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Info

Publication number
SG11201705928XA
SG11201705928XA SG11201705928XA SG11201705928XA SG11201705928XA SG 11201705928X A SG11201705928X A SG 11201705928XA SG 11201705928X A SG11201705928X A SG 11201705928XA SG 11201705928X A SG11201705928X A SG 11201705928XA SG 11201705928X A SG11201705928X A SG 11201705928XA
Authority
SG
Singapore
Prior art keywords
methylsulfonyl
dcm
treatment
dilated cardiomyopathy
urea compounds
Prior art date
Application number
SG11201705928XA
Other languages
English (en)
Inventor
Johan Oslob
Danielle Aubele
Jae Kim
Robert Mcdowell
Yonghong Song
Arvinder Sran
Min Zhong
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of SG11201705928XA publication Critical patent/SG11201705928XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201705928XA 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) SG11201705928XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Publications (1)

Publication Number Publication Date
SG11201705928XA true SG11201705928XA (en) 2017-08-30

Family

ID=55275230

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201705928XA SG11201705928XA (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
SG10201913047UA SG10201913047UA (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913047UA SG10201913047UA (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Country Status (36)

Country Link
US (1) US9925177B2 (enrdf_load_stackoverflow)
EP (2) EP4234017A3 (enrdf_load_stackoverflow)
JP (1) JP6712275B2 (enrdf_load_stackoverflow)
KR (3) KR20240119163A (enrdf_load_stackoverflow)
CN (3) CN111393414B (enrdf_load_stackoverflow)
AU (4) AU2016209200B2 (enrdf_load_stackoverflow)
BR (1) BR112017015627B1 (enrdf_load_stackoverflow)
CA (1) CA2974370C (enrdf_load_stackoverflow)
CL (1) CL2017001871A1 (enrdf_load_stackoverflow)
CO (1) CO2017008398A2 (enrdf_load_stackoverflow)
CR (1) CR20170370A (enrdf_load_stackoverflow)
DK (1) DK3247707T3 (enrdf_load_stackoverflow)
DO (2) DOP2017000166A (enrdf_load_stackoverflow)
EA (1) EA036923B1 (enrdf_load_stackoverflow)
EC (1) ECSP17054181A (enrdf_load_stackoverflow)
ES (1) ES2953480T3 (enrdf_load_stackoverflow)
FI (1) FI3247707T3 (enrdf_load_stackoverflow)
GT (1) GT201700163A (enrdf_load_stackoverflow)
HR (1) HRP20230737T1 (enrdf_load_stackoverflow)
HU (1) HUE063410T2 (enrdf_load_stackoverflow)
IL (6) IL295547A (enrdf_load_stackoverflow)
LT (1) LT3247707T (enrdf_load_stackoverflow)
MX (3) MX385960B (enrdf_load_stackoverflow)
MY (1) MY203427A (enrdf_load_stackoverflow)
PE (2) PE20171511A1 (enrdf_load_stackoverflow)
PH (2) PH12021553074A1 (enrdf_load_stackoverflow)
PL (1) PL3247707T3 (enrdf_load_stackoverflow)
PT (1) PT3247707T (enrdf_load_stackoverflow)
RS (1) RS64432B1 (enrdf_load_stackoverflow)
SG (2) SG11201705928XA (enrdf_load_stackoverflow)
SI (1) SI3247707T1 (enrdf_load_stackoverflow)
SM (1) SMT202300259T1 (enrdf_load_stackoverflow)
TN (1) TN2017000320A1 (enrdf_load_stackoverflow)
UA (1) UA119905C2 (enrdf_load_stackoverflow)
WO (1) WO2016118774A1 (enrdf_load_stackoverflow)
ZA (1) ZA201704777B (enrdf_load_stackoverflow)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
TWI835770B (zh) 2018-01-19 2024-03-21 美商胞質動力學公司 心肌節抑制劑
WO2019150392A1 (en) * 2018-02-01 2019-08-08 Srf Limited Pyrazole compounds and preparation thereof
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020005888A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
AU2020315605A1 (en) * 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
PH12022552787A1 (en) 2020-05-05 2024-03-25 Nuvalent Inc Heteroaromatic macrocyclic ether chemotherapeutic agents
MX2022015488A (es) * 2020-06-15 2023-03-21 Myokardia Inc Tratamiento para la disfuncion auricular.
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
AR125026A1 (es) 2021-03-04 2023-05-31 Cytokinetics Inc Inhibidores del sarcómero cardíaco
MX2024003738A (es) 2021-10-01 2024-06-19 Nuvalent Inc Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
MY144470A (en) * 2004-06-17 2011-09-30 Cytokinetics Inc Compounds, compositions and methods
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CA2778175A1 (en) * 2009-11-11 2011-05-19 Yoshihiro Horiuchi 8-azabicyclo[3.2.1]octane-8-carboxamide derivative

Also Published As

Publication number Publication date
WO2016118774A1 (en) 2016-07-28
MX394704B (es) 2025-03-24
HRP20230737T1 (hr) 2023-10-13
AU2024266781A1 (en) 2024-12-12
MY203427A (en) 2024-06-27
RS64432B1 (sr) 2023-09-29
KR102688851B1 (ko) 2024-07-29
EP4234017A2 (en) 2023-08-30
BR112017015627A2 (pt) 2018-03-13
PT3247707T (pt) 2023-08-31
HK1246775A1 (en) 2018-09-14
AU2023200361A1 (en) 2023-02-23
IL271034A (en) 2020-01-30
SI3247707T1 (sl) 2023-10-30
PL3247707T3 (pl) 2023-12-11
CN107428719B (zh) 2020-03-27
IL253552B (en) 2019-12-31
PH12017501279B1 (en) 2023-06-16
CN107428719A (zh) 2017-12-01
FI3247707T3 (fi) 2023-08-22
BR112017015627B1 (pt) 2022-11-16
KR20170113578A (ko) 2017-10-12
IL286369A (en) 2021-10-31
CN111393414B (zh) 2024-05-07
CN118164961A (zh) 2024-06-11
KR20240119163A (ko) 2024-08-06
CL2017001871A1 (es) 2018-04-13
CR20170370A (es) 2017-10-20
IL253552A0 (en) 2017-09-28
IL279247A (en) 2021-01-31
PE20171511A1 (es) 2017-10-20
ECSP17054181A (es) 2019-02-28
IL313678A (en) 2024-08-01
UA119905C2 (uk) 2019-08-27
KR20230145504A (ko) 2023-10-17
EP3247707A1 (en) 2017-11-29
LT3247707T (lt) 2023-08-25
AU2016209200A1 (en) 2017-08-10
TN2017000320A1 (en) 2019-01-16
SMT202300259T1 (it) 2023-09-06
MX2021010778A (es) 2022-08-11
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
DOP2022000172A (es) 2022-09-30
DK3247707T3 (da) 2023-07-03
EP4234017A3 (en) 2023-10-18
MX2022007040A (es) 2022-06-24
SG10201913047UA (en) 2020-02-27
AU2020244490A1 (en) 2020-10-29
KR102585550B1 (ko) 2023-10-10
ZA201704777B (en) 2023-07-26
NZ734020A (en) 2023-11-24
CN111393414A (zh) 2020-07-10
CA2974370A1 (en) 2016-07-28
EA036923B1 (ru) 2021-01-15
AU2023200361B2 (en) 2024-08-22
EA201791656A1 (ru) 2017-11-30
HUE063410T2 (hu) 2024-01-28
US9925177B2 (en) 2018-03-27
MX385960B (es) 2025-03-18
GT201700163A (es) 2018-10-18
MX2017009540A (es) 2017-10-20
AU2020244490B2 (en) 2022-12-01
JP6712275B2 (ja) 2020-06-17
AU2016209200B2 (en) 2020-07-02
US20160243100A1 (en) 2016-08-25
PE20212253A1 (es) 2021-11-24
CA2974370C (en) 2023-10-31
PH12021553074A1 (en) 2023-03-06
ES2953480T3 (es) 2023-11-13
JP2018502883A (ja) 2018-02-01
PH12017501279A1 (en) 2018-01-29
IL295547A (en) 2022-10-01
DOP2017000166A (es) 2017-10-15

Similar Documents

Publication Publication Date Title
IL286369A (en) Piperidine-4-methylsulfonyl-modified urea compounds for the treatment of dilated cardiomyopathy (dcm)
IL268799A (en) Modified cyclic dinucleotide compounds
LT3109223T (lt) Junginys, skirtas karbamido turinčių trąšų apdorojimui
GB201504689D0 (en) Chemical compounds
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
GB201503720D0 (en) Chemical compound
GB201501025D0 (en) Chemical compounds
IL258530B (en) Process for the preparation of organic bromides
GB201512286D0 (en) Chemical compounds
ZA201708566B (en) Imidazodiazepine compound
HK40112260A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
HK40027481B (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
HK40100462A (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
PT3286198T (pt) Compostos para tratar condições pruriginosas
PL3131890T3 (pl) Związki do leczenia zakażeń wirusowych
GB201401198D0 (en) Process for the syntheis of substituted urea compounds
GB201519316D0 (en) Chemical compounds
GB201511123D0 (en) Chemical Compounds
GB201507366D0 (en) Organic semiconductor compounds
GB201507365D0 (en) Organic semiconductor compounds